Biogen, Elan Moving Forward With sBLA for Tysabri

Drug Industry Daily
KEYWORDS FDA
A A

Biogen Idec and Elan plan to file a supplemental biologics application (sBLA) for Tysabri in the “coming weeks” — a move the firms hope will lead to a relaunch of the withdrawn multiple sclerosis (MS) drug.

To View This Article:

Login

Subscribe To Drug Industry Daily